EUVIMEDEUVIMED entdecken
Open Access

Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR -Mutant Transformed Small Cell Lung Cancer

Alissa J Cooper iD, Benjamin Herzberg, Mitchell Parma iD, Kaiwen Wang iD, Laura Alder iD, Urs M Weber iD, Tejas Patil iD, Utsav Joshi iD, Sonam Puri iD, Anjali Saqi, Phoebe Clark iD, Carl M Gay und 11 weitere

JCO Precision Oncology · 2025-10 · (9)

DOI: 10.1200/po-25-00538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-10. Verfasst von Alissa J Cooper und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Hematology/Oncology, Columbia University Irving Medical Center, Herzberg Irving Comprehensive Cancer Center, New York, NY.
  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Thoracic Oncology, Duke Cancer Institute, Durham, NC.
  • Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO.

ORCID-Profile: Alissa J Cooper, Mitchell Parma, Kaiwen Wang, Laura Alder, Urs M Weber, Tejas Patil, Utsav Joshi, Sonam Puri, Phoebe Clark, Tina Cascone, Janet Tu, Thomas E Stinchcombe, Charles M Rudin, Catherine A Shu, Lauren A Byers, Helena Yu, Bingnan Zhang

Förderung

  • NCI NIH HHS

Zitieren

APA

Cooper, A. J., Herzberg, B., Parma, M., Wang, K., Alder, L., Weber, U. M., Patil, T., Joshi, U., Puri, S., Saqi, A., Clark, P., Gay, C. M., Cascone, T., Singhi, E. K., Blumenschein, G., Skoulidis, F., Tu, J., Stinchcombe, T. E., Rudin, C. M., …, & Zhang, B. (2025). Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR -Mutant Transformed Small Cell Lung Cancer. JCO Precision Oncology. https://doi.org/10.1200/po-25-00538

Vancouver

Cooper AJ, Herzberg B, Parma M, Wang K, Alder L, Weber UM, et al. Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR -Mutant Transformed Small Cell Lung Cancer. JCO Precision Oncology. 2025. doi:10.1200/po-25-00538

BibTeX
@article{Cooper2025,
  author = {Cooper, Alissa J and Herzberg, Benjamin and Parma, Mitchell and Wang, Kaiwen and Alder, Laura and Weber, Urs M and Patil, Tejas and Joshi, Utsav and Puri, Sonam and Saqi, Anjali and Clark, Phoebe and Gay, Carl M and Cascone, Tina and Singhi, Eric K and Blumenschein, George and Skoulidis, Ferdinandos and Tu, Janet and Stinchcombe, Thomas E and Rudin, Charles M and Shu, Catherine A and Byers, Lauren A and Yu, Helena and Zhang, Bingnan},
  title = {Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR -Mutant Transformed Small Cell Lung Cancer},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po-25-00538}
}
Kostenlos starten →